Amicus Therapeutics
FOLD
FOLD was delisted on the 24th of April, 2026.
136 hedge funds and large institutions have $1.1B invested in Amicus Therapeutics in 2016 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 53 increasing their positions, 34 reducing their positions, and 17 closing their positions.
323% more call options, than puts
Call options by funds: $19.6M | Put options by funds: $4.63M
56% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 34
41% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 17
40% more capital invested
Capital invested by funds: $781M → $1.1B (+$316M)
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
5% more funds holding
Funds holding: 130 → 136 (+6)
4.56% more ownership
Funds ownership: 99.65% → 104.2% (+4.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
+$27.2M |
| 2 |
Jennison Associates
New York
|
+$18.6M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$15.5M |
| 4 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$14.5M |
| 5 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$11.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$33.3M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$10.4M |
| 3 |
PA
Perceptive Advisors
New York
|
-$7.58M |
| 4 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$4.01M |
| 5 |
JP Morgan Chase
New York
|
-$3.64M |
FOLD Hedge Fund Activity: Q3 2016 in Review
136 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Amicus Therapeutics (FOLD) for Q3 2016, worth a combined $1.1B — up 40% from $781M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new FOLD positions and 17 closed out — a net gain of 7 holders — while 53 added to existing stakes and 34 trimmed.
The largest buyer was Victory Capital Management, opening a new position worth an estimated $27.2M. The largest seller was Pictet Asset Management (UK), exiting entirely with an estimated $33.3M sold.
- 136 institutional investors held Amicus Therapeutics (FOLD) as of Q3 2016, up from 130 in Q2 2016.
- Funds reported $1.1B of Amicus Therapeutics stock for Q3 2016, up 40% quarter-over-quarter.
- 24 funds opened new Amicus Therapeutics positions in Q3 2016 and 17 closed out, a net change of +7 holders.
- The largest Amicus Therapeutics buyer in Q3 2016 was Victory Capital Management, an estimated $27.2M added.
- The largest Amicus Therapeutics seller in Q3 2016 was Pictet Asset Management (UK), an estimated $33.3M sold.
Based on aggregated 13F filings for Q3 2016.